[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646387":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":31,"collaborators":11,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":11,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1：HRS-4642+NALIRIFOX","EXPERIMENTAL",null,[13],"Drug: HRS-4642+NALIRIFOX",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2：HRS-4642+NALIRIFOX+Adebrelimab（4 cycles of neoadjuvant therapy）",[17],"Drug: HRS-4642+NALIRIFOX+Adebrelimab",{"label":19,"type":10,"description":11,"interventionNames":20},"Arm 3：HRS-4642+NALIRIFOX+Adebrelimab（6 cycles of neoadjuvant therapy）",[17],[22,26,29],{"type":23,"name":24,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","HRS-4642+NALIRIFOX",[9],{"type":23,"name":27,"description":27,"armGroupLabels":28,"otherNames":11},"HRS-4642+NALIRIFOX+Adebrelimab",[15],{"type":23,"name":27,"description":27,"armGroupLabels":30,"otherNames":11},[19],{"type":32,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100646387","phase-2-neoadjuvant-hrs-4642-plus-chemotherapy-with-or-without-immunotherapy-for-pancreatic-cancer-100646387",false,"NCT07691593","Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","An Exploratory Clinical Study of HRS-4642 in Combination With Chemotherapy With or Without Adebrelimab as Neoadjuvant Therapy for Pancreatic Cancer","Inclusion Criteria:\n\n1. Male and female participants aged 18-70 (including those who are 18 and 70 years old)；\n2. Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1);\n3. Life expectancy ≥ 12 weeks;\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;\n5. Adequate marrow and organ function;\n\nExclusion Criteria:\n\n1. Prior receipt of any anti-tumor therapy, including but not limited to systemic chemotherapy, radiotherapy, interventional therapy, immunotherapy, targeted therapy, and anti-tumor traditional Chinese medicine therapy;\n2. Presence of distant metastatic lesions confirmed by imaging;\n3. Known hypersensitivity to the investigational drug or any of its excipients;\n4. Presence of any serious or uncontrolled systemic disease;\n5. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n6. Clinically significant acute or chronic pancreatitis;\n7. Participation in any interventional clinical trial involving drugs or medical devices within 4 weeks prior to the first administration of study treatment;\n8. Vaccination with live or live-attenuated vaccines within 4 weeks prior to the first dose of the investigational drug;\n9. Any other condition that, in the judgment of the investigator, makes the subject unsuitable for enrollment.","ALL","18 Years","70 Years",{"count":44,"type":45},60,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.",[51],"Pancreatic Cancer","NOT_YET_RECRUITING","2026-07-08",{"date":55,"type":56},"2026-07-09","ACTUAL",{"date":58,"type":45},"2026-06",{"date":60,"type":45},"2028-10",{"name":5,"class":6}]